It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.

With so many weight loss medications on the market, it’s easy to feel overwhelmed by the options. From brand-name heavy hitters to compounded varieties, each promises to help shed pounds. But a recent head-to-head trial comparing Zepbound vs.

Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a clinical trial show 20% of participants who took Zepbound achieved significant weight loss compared to nearly 14% of participants who took Wegovy.

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their SURMOUNT-5 phase clinical trial on Wednesday which is the first time both GLP1s have been compared side-by-side.

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.

Cannabis might help with weight loss by targeting the endocannabinoid system, potentially suppressing appetite, boosting metabolism, and offering new, less invasive treatments for obesity and

For the uninitiated, both Zepbound (tirzepatide) and Wegovy (semaglutide) are weight loss drugs. They target hormones that influence metabolism and appetite, but they operate through different mechanisms.